ETONOGESTREL AND ETHINYL ESTRADIOL

Hormone

Vaginal

Mechanism of Action

12.1 Mechanism of Action Combination hormonal contraceptives act by suppression of gonadotropins. Although the primary effect of this action is inhibition of ovulation, other alterations include changes in the cervical mucus (which increase the difficulty of sperm entry into the uterus) and the endometrium (which reduce the likelihood of implantation).

Indications

See full prescribing information

Contraindications

• if over age 35 [see Boxed Warning and Warnings and Precautions (5.1) ] Have deep vein thrombosis or pulmonary embolism
• subacute bacterial endocarditis with valvular disease
• benign or malignant or liver disease [see Warnings and Precautions (5.3) and Use in Specific Populations (8.6) ] Undiagnosed abnormal uterine bleeding [see Warnings and Precautions (5.11) ] Pregnancy
• because there is no reason to use CHCs during pregnancy [see Use in Specific Populations (8.1) ] Current diagnosis of
• or history of

FDA Warnings

5 WARNINGS AND PRECAUTIONS Vascular risks: Stop NuvaRing use if a thrombotic event occurs
] If feasible, stop NuvaRing at least four weeks before and through two weeks after major surgery or other surgeries known to have an elevated risk of thromboembolism, and during and following prolonged immobilization
The risk of postpartum thromboembolism decreases after the third postpartum week, whereas the risk of ovulation increases after the third postpartum week
The use of CHCs increases the risk of VTE

Known Side Effects

0 documented side effects by frequency

No structured side effect data available.

Community Discussions

No community discussions found for ETONOGESTREL AND ETHINYL ESTRADIOL yet.

Compare With

15 available comparisons

Formulations

Dosage Forms

Tablet

Route

Vaginal